Similar effects were also observed in a second strain of mice (C57BL/6). Because hematopoietic system is most sensitive to total body irradiation, we next sought to determine the effects of IGF-1 on hematopoietic recovery. Compared with the saline control group, treatment with IGF-1 significantly accelerated the recovery of both platelets and red cells in blood in irradiated (7.5 Gy) BALB/c mice when measured at day +14 post irradiation. Numbers of total bone marrow cells as well as hematopoietic stem cells and progenitors per femur were significantly increased in IGF-1-treated mice compared with the control group. Using flow cytometric analysis and a novel single cell assay, we demonstrated that IGF-1 protected both hematopoietic stem cells and progenitors from radiation-induced apoptosis and cell death. Using an in vitro culture system, we also demonstrated that IGF-1 was able to facilitate the proliferation and differentiation of non-irradiated and irradiated hematopoietic progenitors but not stem cells. These data indicate that IGF-1 mitigates against lethal irradiation through protecting hematopoietic stem/progenitor cells from radiation-induced apoptosis and also through enhancing proliferation and differentiation of surviving hematopoietic progenitor cells. Higher absolute lymphocyte count at day 30 (ALC 30) after allogeniec hematopoietic stem cell transplant (HSCT) has been associated with better overall survival (OS). This has largely been evaluated in small retrospective studies with cyclosposrine and methotrexate for graft vs. host disease (GVHD) prophylaxis. ALC 30 and its impact on patient (pt) outcomes after tacrolimus (Tac) and mycophenolate mofetil (MMF) is largely unknown.
We retrospectively evaluated a cohort of 414 consecutive pts between January 2005 and June 2010 at Karmanos Cancer Center. Patients with GVHD or death before day 30 post transplant were excluded from the analysis (N ¼33). We performed a multivariate logistic regression analysis to determine donor/recipient predictors of ALC 30. Cox proportional hazard models were used to assess the Introduction: Lymphocyte recovery after T cell depleted allogeneic stem cell transplant (allo-HCT) is delayed for at least 6-9 months, particularly after alemtuzumab (AL) administration. Most studies predominantly involving matched sibling donors and T cell replete allo-HCT have shown that early lymphocyte recovery by day 30 is associated with better OS and EFS. Impact of absolute lymphocyte count (ALC) after AL based allo-HCT using unrelated donors (UD) is unknown. Methods: We retrospectively evaluated 30 consecutive patients (pts) who underwent allo-HCT from UDs at Markey Cancer Center between January 2010 and May 2012. The primary end point of the study was to evaluate the impact of ALC on transplant outcomes and assess any predictors of higher ALC. Cox proportional hazards model was used for time to event analysis and Odds Ratios were calculated using logistic regression to evaluate for predictors for ALC 300 at day 90. AL dose used was 60 mg (20 mg daily x 3 days). Low relapse risk was defined as AML and ALL in CR1, MDS with less than 10% blasts, CLL/NHL/HL with PR and or <5 cm lymphadenopathy and CML in chronic phase. At day 90 ALC <300 x 106/ml was associated with higher mortality (HR¼4.65, P ¼ .03). In our study, ALC 90 was not associated with GVHD, NRM, CMV reactivation or relapse. ALC 90 >300 x 106/ml was also not associated with donor's sex, CMV status, pt's age, sex, CMV status, CD 34 cells infused, relapse risk, HLA mismatch, source of stem cells or type of conditioning regimen.
After a median follow up of 431 days (118-909), 16 patients are alive. Causes of death were GVHD (6), relapse (2), graft failure (2), infection (2), VOD (1) and hemorrhage (1). Five pts have relapsed. Cumulative incidence of aGVHD (II-IV) was 36.7%, cGVHD (mild, moderate) 13.3% and CMV reactivation (46.7%). Conclusion: AL is associated with delayed recovery of ALC post allo-HCT. ALC 90 300 x 106/ml was associated with four fold higher hazard of death after AL as compared to patients with ALC 90 > 300 x 106/ml at any given time. Further studies are needed to confirm our preliminary findings, to elucidate factors associated with higher ALC90, and ultimately to test proposed interventions to improve ALC90 after allo-HCT. 
